MEDP
VENTE TOTALE: 124 366 titres (~75 990 626,06 $ US)
- Insiders
- Troendle August J., Kraft Robert O., Carley Brian T, DAVENPORT FRED B JR, McCarthy Cornelius P. III
- Total bought
- —
- Total sold
- $75,990,626
- Last activity
- 2026-08-27
- Last synced
-
2026-09-02 21:34:12
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-01
MEDP shows solid long-term operational fundamentals (ROE, ROIC) but is undermined by tight short-term liquidity (current ratio 0.74), elevated leverage, and stretched valuation multiples.
The first sentence of the analysis written for MEDP on 2026-09-01 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 30.1% | 31.1% | 27.8% | 29.6% | 28.7% | |
| Ebit Margin | 21.4% | 22.6% | 17.8% | 19.6% | 17.7% | |
| Ebitda Margin | 22.5% | 24.0% | 19.2% | 21.1% | 19.5% | |
| Operating Profit Margin | 21.1% | 21.2% | 17.9% | 19.1% | 17.4% | |
| Pretax Profit Margin | 21.4% | 22.6% | 17.8% | 19.4% | 17.7% | |
| Continuous Operations Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Net Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Bottom Line Profit Margin | 17.8% | 19.2% | 15.0% | 16.8% | 15.9% | |
| Current Ratio | 0.736 | 0.932 | 0.642 | 0.416 | 1.240 | |
| Quick Ratio | 0.736 | 0.932 | 0.642 | 0.416 | 1.240 | |
| Solvency Ratio | 0.316 | 0.340 | 0.282 | 0.277 | 0.287 | |
| Cash Ratio | 0.370 | 0.606 | 0.265 | 0.035 | 0.828 | |
| Price To Earnings Ratio | 35.911 | 25.439 | 33.318 | 28.059 | 43.012 | |
| Price To Earnings Growth Ratio | 1.818 | 0.606 | 1.547 | 0.566 | 1.768 | |
| Forward Price To Earnings Growth Ratio | 1.818 | 0.606 | 1.547 | 0.566 | 1.768 | |
| Price To Earnings Diluted Ratio | 36.757 | 26.305 | 34.519 | 29.177 | 45.247 | |
| Price To Earnings Diluted Growth Ratio | 1.752 | 0.623 | 1.571 | 0.568 | 1.791 | |
| Price To Book Ratio | 35.292 | 12.458 | 16.848 | 17.805 | 8.191 | |
| Price To Sales Ratio | 6.403 | 4.877 | 4.994 | 4.712 | 6.832 | |
| Price To Free Cash Flow Ratio | 23.760 | 17.972 | 23.737 | 19.590 | 33.205 | |
| Price To Operating Cash Flow Ratio | 22.716 | 16.893 | 21.730 | 17.728 | 29.640 | |
| Debt To Assets Ratio | 0.127 | 0.071 | 0.086 | 0.140 | 0.079 | |
| Debt To Equity Ratio | 0.546 | 0.181 | 0.254 | 0.489 | 0.137 | |
| Debt To Capital Ratio | 0.353 | 0.153 | 0.203 | 0.328 | 0.121 | |
| Long Term Debt To Capital Ratio | 0.198 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 4.303 | 2.545 | 2.964 | 3.500 | 1.742 | |
| Working Capital Turnover Ratio | -11.784 | -10.373 | -4.710 | -8.695 | 13.662 | |
| Operating Cash Flow Ratio | 0.531 | 0.551 | 0.468 | 0.483 | 0.473 | |
| Operating Cash Flow Sales Ratio | 0.282 | 0.289 | 0.230 | 0.266 | 0.231 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | 0.940 | 0.915 | 0.905 | 0.893 | |
| Debt Service Coverage Ratio | 20.649 | 18.620 | 634.480 | 5.115 | 1,934.019 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 690.215 | 95.937 | 1,891.571 | |
| Short Term Operating Cash Flow Coverage Ratio | 30.730 | 26.142 | 0.000 | 7.761 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 2.847 | 4.072 | 3.049 | 2.055 | 2.011 | |
| Capital Expenditure Coverage Ratio | 22.746 | 16.658 | 11.825 | 10.522 | 9.314 | |
| Dividend Paid And Capex Coverage Ratio | 22.746 | 16.658 | 11.825 | 10.522 | 9.314 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 27.966 | 19.330 | 25.694 | 22.850 | 33.507 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 30.1% | ▼-1.1% | ▲0.6% |
| Ebit Margin | 21.4% | ▼-1.1% | ▲1.6% |
| Ebitda Margin | 22.6% | ▼-1.4% | ▲1.3% |
| Operating Profit Margin | 21.1% | ▼-0.1% | ▲1.8% |
| Pretax Profit Margin | 21.4% | ▼-1.1% | ▲1.7% |
| Continuous Operations Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Net Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Bottom Line Profit Margin | 17.8% | ▼-1.3% | ▲0.9% |
| Current Ratio | 0.737 | ▼-0.195 | ▼-0.057 |
| Quick Ratio | 0.737 | ▼-0.195 | ▼-0.057 |
| Solvency Ratio | 0.316 | ▼-0.024 | ▲0.016 |
| Cash Ratio | 0.370 | ▼-0.236 | ▼-0.051 |
| Price To Earnings Ratio | 35.911 | ▲10.472 | ▲2.763 |
| Price To Earnings Growth Ratio | 1.818 | ▲1.212 | ▲0.557 |
| Forward Price To Earnings Growth Ratio | 1.818 | ▲1.212 | ▲0.557 |
| Price To Earnings Diluted Ratio | 36.757 | ▲10.452 | ▲2.356 |
| Price To Earnings Diluted Growth Ratio | 1.752 | ▲1.129 | ▲0.491 |
| Price To Book Ratio | 35.292 | ▲22.833 | ▲17.173 |
| Price To Sales Ratio | 6.403 | ▲1.527 | ▲0.840 |
| Price To Free Cash Flow Ratio | 23.760 | ▲5.788 | ▲0.107 |
| Price To Operating Cash Flow Ratio | 22.716 | ▲5.822 | ▲0.974 |
| Debt To Assets Ratio | 0.127 | ▲0.056 | ▲0.026 |
| Debt To Equity Ratio | 0.546 | ▲0.364 | ▲0.224 |
| Debt To Capital Ratio | 0.353 | ▲0.200 | ▲0.121 |
| Long Term Debt To Capital Ratio | 0.198 | ▲0.198 | ▲0.159 |
| Financial Leverage Ratio | 4.303 | ▲1.758 | ▲1.292 |
| Working Capital Turnover Ratio | -11.784 | ▼-1.410 | ▼-7.404 |
| Operating Cash Flow Ratio | 0.531 | ▼-0.020 | ▲0.030 |
| Operating Cash Flow Sales Ratio | 0.282 | ▼-0.007 | ▲0.023 |
| Free Cash Flow Operating Cash Flow Ratio | 0.956 | ▲0.016 | ▲0.034 |
| Debt Service Coverage Ratio | 20.649 | ▲2.029 | ▼-501.927 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▼-535.545 |
| Short Term Operating Cash Flow Coverage Ratio | 30.730 | ▲4.589 | ▲17.804 |
| Operating Cash Flow Coverage Ratio | 2.847 | ▼-1.224 | ▲0.041 |
| Capital Expenditure Coverage Ratio | 22.746 | ▲6.088 | ▲8.533 |
| Dividend Paid And Capex Coverage Ratio | 22.746 | ▲6.088 | ▲8.533 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 27.966 | ▲8.636 | ▲2.097 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $16.20B | $10.28B | $9.42B | $6.88B | $7.81B | |
| Enterprise value | $15.95B | $9.76B | $9.31B | $7.04B | $7.47B | |
| EV / Sales | 6.31x | 4.63x | 4.94x | 4.82x | 6.54x | |
| EV / Op. cash flow | 22.37x | 16.04x | 21.49x | 18.14x | 28.39x | |
| EV / Free cash flow | 23.40x | 17.06x | 23.48x | 20.05x | 31.80x | |
| EV / EBITDA | 27.97x | 19.33x | 25.69x | 22.85x | 33.51x | |
| Net debt / EBITDA | -0.43x | -1.03x | -0.28x | 0.52x | -1.48x | |
| Current ratio | 0.74x | 0.93x | 0.64x | 0.42x | 1.24x | |
| Income quality | 1.58x | 1.51x | 1.53x | 1.58x | 1.45x | |
| Graham number | $75 | $89 | $61 | $45 | $55 | |
| Graham net-net | -$25 | -$12 | -$20 | -$23 | -$3 | |
| Tax burden | 83.2% | 85.0% | 84.2% | 86.7% | 90.1% | |
| Interest burden | 100.0% | 100.0% | 99.9% | 99.0% | 99.9% | |
| Working capital | -$354.1M | -$75.3M | -$331.3M | -$469.5M | $133.7M | |
| Invested capital | $590.6M | $873.7M | $632.3M | $479.8M | $1.06B | |
| Return on assets | 22.8% | 19.2% | 17.1% | 18.1% | 11.0% | |
| Operating ROA | 26.2% | 23.8% | 22.4% | 18.5% | 13.0% | |
| Return on tangible assets | 35.3% | 28.8% | 29.5% | 37.6% | 19.0% | |
| Return on equity | 98.3% | 49.0% | 50.6% | 63.5% | 19.1% | |
| Return on invested capital | 67.9% | 37.2% | 38.8% | 40.4% | 16.2% | |
| Return on capital employed | 84.7% | 44.9% | 46.0% | 50.8% | 18.0% | |
| Earnings yield | 2.8% | 3.9% | 3.0% | 3.6% | 2.3% | |
| Free cash flow yield | 4.2% | 5.6% | 4.2% | 5.1% | 3.0% | |
| Capex / Op. cash flow | 4.4% | 6.0% | 8.5% | 9.5% | 10.7% | |
| Capex / Depreciation | 115.4% | 124.9% | 139.2% | 165.1% | 133.9% | |
| Capex / Sales | 1.2% | 1.7% | 1.9% | 2.5% | 2.5% | |
| SG&A / Sales | 7.8% | 8.5% | 8.6% | 9.0% | 9.5% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.4% | 1.2% | 1.1% | 1.5% | 1.3% | |
| Intangibles / Total assets | 35.2% | 33.2% | 42.1% | 51.8% | 42.4% | |
| Days sales outstanding | 58d | 51d | 58d | 63d | 60d | |
| Days payables outstanding | 6d | 8d | 9d | 12d | 12d | |
| Operating cycle | 58d | 51d | 58d | 63d | 60d | |
| Cash conversion cycle | 52d | 43d | 49d | 52d | 48d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+57.5%EV / Sales ▲+36.2%EV / EBITDA ▲+44.7%EV / Op. cash flow ▲+6.331Earnings yield ▼-0.011Graham number ▼-13.699
Profitability
Return on equity ▲+0.493Return on assets ▲+0.036Return on invested capital ▲+0.307Return on capital employed ▲+0.398Operating ROA ▲+0.025Income quality ▲+0.075Tax burden ▼-0.018
Efficiency
Days sales outstanding ▲+6.699Days payables outstanding ▼-2.368Operating cycle ▲+6.699Cash conversion cycle ▲+9.067Capex / Sales ▼-0.005R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.195Net debt / EBITDA ▲+0.597Working capital ▼-278800000.000Invested capital ▼-283140000.000Intangibles / Total assets ▲+0.021
Change over 5 years
Valuation
Market cap ▲+107.6%EV / Sales ▼-3.6%EV / EBITDA ▼-16.5%EV / Op. cash flow ▼-6.015Earnings yield ▲+0.005Graham number ▲+19.772
Profitability
Return on equity ▲+0.792Return on assets ▲+0.119Return on invested capital ▲+0.517Return on capital employed ▲+0.667Operating ROA ▲+0.132Income quality ▲+0.133Tax burden ▼-0.069
Efficiency
Days sales outstanding ▼-1.565Days payables outstanding ▼-5.706Operating cycle ▼-1.565Cash conversion cycle ▲+4.142Capex / Sales ▼-0.012R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.503Net debt / EBITDA ▲+1.049Working capital ▼-487819000.000Invested capital ▼-469600000.000Intangibles / Total assets ▼-0.072
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-05-15 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-05-15 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-05-15 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-02-26 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-01-29 | David Taylor | Purchase | $1,001 - $15,000 |
| 2026-01-16 | David Taylor | Sale | $1,001 - $15,000 |
| 2026-01-15 | Gilbert Cisneros | Sale (Full) | $15,001 - $50,000 |
| 2025-10-09 | Gilbert Cisneros | Sale (Partial) | $1,001 - $15,000 |
| 2025-08-04 | Lisa McClain | Sale | $1,001 - $15,000 |
| 2025-07-24 | Gilbert Cisneros | Sale | $1,001 - $15,000 |
| 2025-07-23 | David Taylor | Sale | $1,001 - $15,000 |
| 2025-07-22 | Lisa McClain | Purchase | $1,001 - $15,000 |
| 2024-07-26 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2024-06-21 | Josh Gottheimer | Sale | $1,001 - $15,000 |
| 2024-01-24 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2023-11-13 | Michael Patrick Guest | Purchase | $1,001 - $15,000 |
| 2022-07-22 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2021-10-26 | Josh Gottheimer | Sale (Partial) | $1,001 - $15,000 |
| 2020-12-10 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-12-08 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
| 2020-11-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2020-10-29 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-01 Why Medpace (MEDP) is a Top Growth Stock for the Long-Term The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here''s why you should take advantage.
- 2026-08-27 American Capital Management Inc. Invests $111.33 Million in Medpace Holdings, Inc. $MEDP American Capital Management Inc. bought a new stake in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 210,217 shares of the company''s stock, valued at approximately $111,329,000. Medpace makes up about 5.0%
- 2026-08-26 Medpace Stock Hovers Near Entry, Offers Second Chance After July Spike Medpace stock is back below a buy point of 628.92. The medical research contractor delivered an earnings beat for its second quarter.
- 2026-08-26 CON vs. MEDP: Which Stock Should Value Investors Buy Now? Investors with an interest in Medical Services stocks have likely encountered both Concentra Group (CON) and Medpace (MEDP). But which of these two stocks presents investors with the better value opportunity right now?
- 2026-08-26 What Investors Should Know About Medpace CEO Troendle Selling $10 Million in Stock The CEO sold 15,978 shares at a weighted-average price of $623.93 over two trading days ending Aug. 24, 2026. The transaction involved shares equal to 3% of Troendle''s direct equity holdings and 0.3% of his total combined stake.
- 2026-08-26 Bank of New York Mellon Corp Takes Position in Medpace Holdings, Inc. $MEDP Bank of New York Mellon Corp bought a new stake in Medpace Holdings, Inc. (NASDAQ: MEDP) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 146,588 shares of the company''s stock, valued at approximately $77,632,000. Bank of
- 2026-08-22 B. Metzler seel. Sohn & Co. AG Invests $4.74 Million in Medpace Holdings, Inc. $MEDP B. Metzler seel. Sohn and Co. AG purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,944 shares of the company''s stock, valued at approximately $4,737,000. Several other
- 2026-08-22 Allworth Financial LP Makes New Investment in Medpace Holdings, Inc. $MEDP Allworth Financial LP acquired a new stake in Medpace Holdings, Inc. (NASDAQ: MEDP) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,894 shares of the company''s stock, valued at approximately $2,062,000. A number of other hedge funds
- 2026-08-21 Why Is Medpace (MEDP) Up 1.1% Since Last Earnings Report? Medpace (MEDP) reported earnings 30 days ago. What''s next for the stock?
- 2026-08-20 Abacus FCF Advisors LLC Invests $6.63 Million in Medpace Holdings, Inc. $MEDP Abacus FCF Advisors LLC acquired a new stake in shares of Medpace Holdings, Inc. (NASDAQ: MEDP) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 12,529 shares of the company''s stock, valued at approximately $6,635,000. Several other institutional investors